Click on image to view larger version.

Figure 2 Targets of "Atrial-Selective" Antiarrhythmic Drugs

This figure presents a simplified cell with sarcolemmal membrane and ion currents and transporters that have served as targets for atrial-selective therapy shown. Pharmacologic agents discussed in the paper are presented in boxes, and filled arrows denote inhibition of specific currents. Rotigaptide is a connexin (Cx) activator—as illustrated by the "+" symbol. JTV-519 stabilizes ryanodine-receptor (RyR) and calstabin complexes. DPO = diphenylphosphine oxide; SR = sarcoplasmic reticulum; other abbreviations as in Figure 1.